Inducer of glucuronyl transferase UGT1A1 and application thereof

The inducer of glucuronide transferase UGT1A1 significantly improves its expression, solves the problems of insufficient drug metabolism and adverse reactions caused by insufficient UGT1A1 activity, and achieves efficient metabolism of bilirubin and drugs, and treats related diseases and side effects.

CN119055631APending Publication Date: 2024-12-03LINYI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411249147.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art cannot effectively induce the uridine diphosphate glucuronide transferase UGT1A1, resulting in insufficient drug metabolism, triggering adverse reactions such as neutropenia and diarrhea. The reduced activity of UGT1A1 will lead to Gilbert syndrome and Crigler-Najjar syndrome. .

Method used

Provides an inducer of the glucuronide transferase UGT1A1, which enhances its metabolic capacity by significantly increasing the mRNA and protein expression of UGT1A1 enzyme, reduces the toxic side effects of bilirubin and drugs, and is used to treat related diseases and improves drug metabolic clearance.

Benefits of technology

Significantly improve the induction ability of UGT1A1, reduce the toxic side effects of bilirubin and drugs, effectively treat Gilbert syndrome and Crigler-Najjar syndrome, reduce adverse reactions such as drug neutropenia and diarrhea, and improve the efficiency of drug metabolism clearance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055631A_ABST
    Figure CN119055631A_ABST
Patent Text Reader

Abstract

The invention discloses an inducer of glucuronyl transferase UGT1A1 and application of the inducer, and belongs to the technical field of medicines. The inducer of the UGT1A1 disclosed by the invention is fructus psoraleae isoflavone or fructus psoraleae flavanone methyl ether. The inducer of UGT1A1 disclosed by the invention can be used for treating diseases such as Gilbert syndrome, Crigler-Najjar syndrome and the like caused by low activity of UGT1A1 by inducing up-regulation of expression of glucuronyl transferase UGT1A1, improving metabolic clearance of endogenous and exogenous drugs and reducing toxic and side effects caused by therapeutic drugs. In a human cell induction experiment, the inducer of the UGT1A1 can obviously induce the expression and activity of the UGT1A1 in HepG2 cells, and the induction capacity of the inducer to the UGT1A1 is higher than that of a positive control drug chrysin. The discovery of the UGT1A1 inducer provides reference for the use of clinical treatment drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and more particularly to an inducer of glucuronyl transferase UGT1A1 and application thereof. Background Art

[0002] Uridine diphosphate glucuronosyltransferase (UGT) is a very important phase II metabolic enzyme, accounting for about 35% of phase II drug metabolism. Based on its sequence similarity, it is divided into four families: UGT1, UGT2, UGT3, and UGT8. The UGT1 family has 9 functional genes, and the UGT2 family has 10 functional genes.

[0003] Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is an extremely important drug metabolizing enzyme, which is widely expressed in the liver and also plays an important role in the stomach, intestines and other organs. Glucuronidation is one of the important detoxification pathways in the body. UGT1A1 catalyzes the combination of glucuronic acid with a variety of exogenous substances containing hydroxyl, amino, carboxyl, sulfur and other groups, increasing the polarity of the original exogenous substances, making them soluble in water and reducing their toxicity, and they are excreted from the body through urine and bile.

[0004] Most categories of drugs are substrates of UGT. Endogenous and exogenous substances such as estradiol, 4-methylumbelliferone and etoposide are glucuronidated by UGT1A1. The cancer treatment drug irinotecan (CPT-11) and its active metabolite SN-38 are also metabolized by UGT1A1. Increasing the activity of UGT1A1 can reduce the adverse reactions of neutropenia and diarrhea caused by anticancer drugs. While UGT1A1 metabolizes drugs, its activity can also be affected by metabolized drugs. Experiments have shown that chrysin, carbamazepine and dexamethasone can induce UGT1A1 enzyme activity. The reduction of UGT1A1 activity has a great impact on human health. As a single metabolic enzyme of bilirubin (BR), if the enzyme activity of UGT1A1 is reduced, jaundice will occur in mild cases, and severe loss of activity will lead to Gilbert syndrome and Crigler-Najjar syndrome.

[0005] Therefore, providing an inducer of glucuronyl transferase UGT1A1 and its application is a problem that those skilled in the art need to solve urgently. Summary of the invention

[0006] In view of this, the present invention provides an inducer of glucuronyl transferase UGT1A1 and application thereof.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] The inducer of glucuronyl transferase UGT1A1 is used to significantly increase the expression of UGT1A1 enzyme mRNA and protein, induce upregulation of UGT1A1 expression, and thereby improve the metabolism of endogenous or exogenous drugs.

[0009] The inducer of glucuronyl transferase UGT1A1 is used to significantly induce the up-regulation of UGT1A1 expression, improve the metabolic capacity of bilirubin, reduce the content of unconjugated bilirubin, and reduce toxic reactions.

[0010] The inducer of glucuronyltransferase UGT1A1 is used for significantly inducing up-regulation of UGT1A1 expression and treating Gilbert syndrome and Crigler-Najjar syndrome caused by decreased UGT1A1 activity.

[0011] The inducer of glucuronyl transferase UGT1A1 is used to significantly induce the up-regulation of UGT1A1 expression, improve the metabolic clearance of drugs, and reduce the occurrence of toxic side effects. For example, the activity of UGT1A1 is increased, the metabolic clearance of CPT-11 is accelerated, and the toxic side effects such as neutropenia and diarrhea are alleviated.

[0012] The inducer of glucuronyl transferase UGT1A1 can be in various dosage forms, such as tablets, granules, capsules, injections, pills and the like.

[0013] The use of inducers of glucuronyl transferase UGT1A1 in treating bilirubin-related diseases or improving drug metabolic clearance. The inducers can be used alone or in combination with other drugs.

[0014] It can be seen from the above technical solution that, compared with the prior art, the present invention discloses an inducer of glucuronyl transferase UGT1A1 and its application, which has the following beneficial effects:

[0015] (1) Strong induction ability: This type of drug has a strong induction ability for UGT1A1, and the induction ability of UGT1A1 is significantly higher than that of the currently recognized positive control drug chrysin.

[0016] (2) High safety: CCK-8 toxicity test was performed at the cellular level, and the cell survival rate was higher than 85% when the drug concentration reached 20 μM.

[0017] (3) UGT1A1 inducers are commercially available and easy to obtain. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0019] Figure 1 The accompanying drawings show the cytotoxicity of the UGT1A1 inducer of the present invention;

[0020] Wherein: A: psoralea corylifolia isoflavones; B: psoralea corylifolia dihydroflavone methyl ether;

[0021] Figure 2 The accompanying drawing shows that the UGT1A1 inducer of the present invention induces the expression of UGT1A1 enzyme mRNA in HepG2 cells;

[0022] Wherein: A: psoralea corylifolia isoflavones; B: psoralea corylifolia dihydroflavone methyl ether;

[0023] Figure 3 The accompanying drawing shows the change of the mRNA expression of UGT1A1 enzyme in HepG2 cells induced by the UGT1A1 inducer of the present invention as a function of concentration;

[0024] Wherein: A: psoralea corylifolia isoflavones; B: psoralea corylifolia dihydroflavone methyl ether;

[0025] Figure 4 The accompanying drawing shows the change of UGT1A1 enzyme mRNA expression in HepG2 cells induced by the UGT1A1 inducer of the present invention over time;

[0026] Wherein: A: psoralea corylifolia isoflavones; B: psoralea corylifolia dihydroflavone methyl ether;

[0027] Figure 5 The accompanying drawing shows the change of the expression of UGT1A1 enzyme protein in HepG2 cells induced by the UGT1A1 inducer of the present invention as a function of concentration;

[0028] Among them: A: Psoralea corylifolia isoflavones; B: Psoralea corylifolia dihydroflavone methyl ether. DETAILED DESCRIPTION

[0029] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0030] DMEM / high glucose medium was purchased from Hyclone, fetal bovine serum was purchased from BI (Shanghai, China), and penicillin-streptomycin was purchased from Solarbio (Beijing, China). Psoralen isoflavones, psoralen dihydroflavonoid methyl ether, and chrysin were purchased from Titan (Shanghai, China). Reverse transcription kit and TB Premix Ex Taq TM (Tli RNaseH plus) kit was purchased from Takara.

[0031] Example 1 Toxicity Assessment of UGT1A1 Inducers (Drugs)

[0032] (1) HepG2 cells were seeded in 96-well plates, with 7,500 cells per well, and incubated in DMEM / high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 24 hours.

[0033] (2) Add drugs (psoralen isoflavones or psoralen dihydroflavone methyl ether) of different concentrations, and add DMSO of the same concentration to the blank control group, with the DMSO content less than 0.5%, and incubate for 48 hours.

[0034] (3) Discard the drug-containing culture medium, add 20 μl of CCK8 solution and 180 μl of serum-free culture medium (DMEM / high glucose medium supplemented with 1% penicillin-streptomycin) to each well, and incubate at 37°C for 30 minutes.

[0035] (4) After the incubation, the absorbance at 450 nm was measured using an ELISA reader.

[0036] The results are as follows Figure 1 As shown, when the concentration of the drug (psoralen isoflavone or psoralen dihydroflavone methyl ether) reaches 20 μM, the cell survival rate is higher than 85%, and the drug is highly safe.

[0037] Example 2

[0038] Real-time fluorescence quantitative PCR to determine the mRNA expression of UGT1A1 enzyme induced by UGT1A1 inducers (drugs)

[0039] (1) HepG2 cells were seeded in 12-well plates, with 150,000 cells per well, and incubated in DMEM / high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 24 hours.

[0040] (2) Add drugs (psoralen isoflavones, psoralen dihydroflavone methyl ether or chrysin) at a concentration of 25 μM, and add DMSO of the same concentration to the blank control group, with the DMSO content being less than 0.5%. Incubate for 72 hours.

[0041] (3) Total mRNA was extracted by the trizol method and reverse transcribed into cDNA using a reverse transcription kit. The total reverse transcription system included 2 μl of 5X PrimeScript RT MasterMix (Perfect Real Time), 500 ng of total RNA, and 10 μl of RNase Free dH2O. The reaction conditions were 37°C for 15 min, 85°C for 5 sec, and 4°C.

[0042] (4) Real-time PCR was used to measure the mRNA expression level of UGT1A1 enzyme in cells with increasing concentrations, using GAPDH as an internal reference. Premix Ex Taq TM (Tli RNaseH plus) kit, prepare the reaction system as follows:

[0043]

[0044]

[0045] The primers used for real-time fluorescence quantitative PCR are as follows:

[0046] GAPDH-F: 5′-CCAGGGCTGCTTTTAACTC-3′; SEQ ID NO.1;

[0047] GAPDH-R: 5′-GCTCCCCCCTGCAAATGA-3′; SEQ ID NO.2;

[0048] UGT1A1-F: 5′-CCTTTGCCTCAGAATTCCTTC-3′; SEQ ID NO.3;

[0049] UGT1A1-R: 5′-ATTGATCCCAAAGAGAAAACCAC-3′; SEQ ID NO.4.

[0050] The reaction procedure was as follows: 1. pre-denaturation, 95°C, 30s; 2. PCR reaction, 95°C, 5s, 60°C, 34s, for a total of 40 cycles.

[0051] The results are as follows Figure 2 As shown, the ability of psoralen isoflavones and psoralen dihydroflavone methyl ether to induce the expression of UGT1A1 enzyme mRNA was higher than that of the positive control group chrysin, and the ability of psoralen isoflavones to induce the expression of UGT1A1 enzyme mRNA was stronger.

[0052] Example 3

[0053] Real-time fluorescence quantitative PCR was used to determine the mRNA expression of UGT1A1 enzyme induced by different concentrations of UGT1A1 inducers (drugs)

[0054] (1) HepG2 cells were seeded in 12-well plates, with 150,000 cells per well, and incubated in DMEM / high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 24 hours.

[0055] (2) Add drugs (psoralen isoflavone or psoralen dihydroflavone methyl ether) at concentrations of 2, 10, and 25 μM, and add DMSO of the same concentration to the blank control group, with the DMSO content being less than 0.5%. Incubate for 72 hours.

[0056] (3) Total mRNA was extracted by the trizol method and reverse transcribed into cDNA using a reverse transcription kit. The total reverse transcription system included 2 μl of 5X PrimeScript RT MasterMix (Perfect Real Time), 500 ng of total RNA, and 10 μl of RNase Free dH2O. The reaction conditions were 37°C for 15 min, 85°C for 5 sec, and 4°C.

[0057] (4) Real-time PCR was used to measure the mRNA expression level of UGT1A1 enzyme in cells with increasing concentrations, using GAPDH as an internal reference. Premix Ex Taq TM (Tli RNaseH plus) kit, prepare the reaction system as follows:

[0058]

[0059]

[0060] The primers used for real-time fluorescence quantitative PCR are as follows: GAPDH-F / R; UGT1A1-F / R.

[0061] The reaction procedure was as follows: 1. pre-denaturation, 95°C, 30s; 2. PCR reaction, 95°C, 5s, 60°C, 34s, for a total of 40 cycles.

[0062] By measuring the induction ability of psoralen isoflavones and psoralen dihydroflavone methyl ether on the expression of UGT1A1 enzyme mRNA, it can be seen that ( Figure 3 ), the induction ability of psoralen isoflavones and psoralen dihydroflavone methyl ether on UGT1A1 increased with the increase of induction concentration.

[0063] Example 4

[0064] Real-time fluorescence quantitative PCR was used to determine the mRNA expression of UGT1A1 enzyme induced by UGT1A1 inducers (drugs) at different times

[0065] (1) HepG2 cells were seeded in 12-well plates, with 150,000 cells per well, and incubated in DMEM / high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 24 hours.

[0066] (2) Add 25 μM drug (psoralen isoflavone or psoralen dihydroflavone methyl ether), and add DMSO of the same concentration to the blank control group, with the DMSO content less than 0.5%.

[0067] (3) At 24 h, 48 h, and 72 h, total mRNA was extracted using the trizol method and reverse transcribed into cDNA using a reverse transcription kit. The total reverse transcription system included 5X PrimeScript RT MasterMix (Perfect Real Time) 2 μl, total RNA 500 ng, and RNase Free dH2O to 10 μl; the reaction conditions were 37°C for 15 min, 85°C for 5 sec, and 4°C.

[0068] (4) Real-time PCR was used to measure the increase in the expression of UGT1A1 mRNA in cells over time, using GAPDH as an internal reference. Premix Ex Taq TM (Tli RNaseH plus) kit, prepare the reaction system as follows:

[0069]

[0070]

[0071] The primers used for real-time fluorescence quantitative PCR are as follows: GAPDH-F / R; UGT1A1-F / R.

[0072] The reaction procedure was as follows: 1. pre-denaturation, 95°C, 30s; 2. PCR reaction, 95°C, 5s, 60°C, 34s, for a total of 40 cycles.

[0073] By measuring the induction ability of psoralen isoflavones and psoralen dihydroflavone methyl ether on the expression of UGT1A1 enzyme mRNA over time, it can be seen that ( Figure 4 ), the induction ability of psoralen isoflavones and psoralen dihydroflavone methyl ether on UGT1A1 increased with the increase of induction time.

[0074] Example 5

[0075] Western blotting to determine the protein expression of UGT1A1 induced by UGT1A1 inducers (compounds)

[0076] (1) HepG2 cells were seeded in 6-well plates and incubated in DMEM / high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 24 hours. The medium was then replaced with DMEM medium containing psoralen isoflavones or psoralen dihydroflavone methyl ether at a compound concentration range of 0-25 μM.

[0077] (2) After 48 hours of culture, cells were lysed using protein extraction reagent RIPA lysis buffer (with PMSF added) and proteins were extracted.

[0078] (3) Western-blot experiment was performed using SDS-PAGE gel and GAPDH was used as an internal reference to detect the protein expression of UGT1A1.

[0079] The results are as follows Figure 5 As shown, in HepG2 cells, the protein expression level of UGT1A1 increased with the increase of psoralen isoflavone concentration; the protein expression level of UGT1A1 also increased with the increase of psoralen dihydroflavone methyl ether concentration.

[0080] The above description of the disclosed embodiments enables those skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Inducers of glucuronyltransferase UGT1A1, It is characterized in that The inducing agent is psoralen isoflavone or psoralen dihydroflavone methyl ether.

2. Use of the inducer of glucuronyl transferase UGT1A1 according to claim 1 in increasing the expression of UGT1A1 enzyme mRNA and protein, inducing up-regulation of UGT1A1 expression, and thereby improving the metabolism of endogenous or exogenous drugs.

3. Use of the inducer of glucuronyl transferase UGT1A1 according to claim 1 in significantly inducing up-regulation of UGT1A1 expression, improving drug metabolism and clearance, and reducing the generation of toxic side effects.

4. Use of the inducer of glucuronyltransferase UGT1A1 according to claim 1 in the preparation of a drug for significantly inducing up-regulation of UGT1A1 expression, improving bilirubin metabolism, and treating hyperbilirubinemia.

5. Use of the inducer of glucuronyl transferase UGT1A1 according to claim 1 in the preparation of drugs for Gilbert syndrome and Crigler-Najjar syndrome.

6. The use according to any one of claims 2 to 5, It is characterized in that The inducer of glucuronyl transferase UGT1A1 is used alone or in combination with other drugs; the dosage form used is tablets, granules, capsules, injections, and pills.